NovaGo Therapeutics is a Swiss biotech company dedicated to developing human antibody therapeutics aimed at promoting nerve growth and regeneration, particularly in the context of spinal cord injuries. The company focuses on addressing the challenges posed by spinal cord injuries, which often result in significant loss of sensation and motor function due to the limited ability of the central nervous system to repair itself. NovaGo's innovative approach involves the development of therapeutic antibodies that target and block the Nogo-A receptor, a known inhibitor of nerve growth. By inhibiting this receptor, NovaGo aims to stimulate nerve repair and enhance functional recovery, with promising results observed in preclinical models.

The therapeutic candidates developed by NovaGo have been identified through high-throughput analysis of human immune repertoires, ensuring a robust selection process. The company has collaborated with Neurimmune AG to refine its lead candidates, which have demonstrated the potential to facilitate nerve fiber regeneration and the formation of new neural connections following injury. With Phase 1b clinical trials anticipated to commence in 2024, NovaGo Therapeutics is positioned to contribute significantly to the field of spinal cord injury treatment, offering hope for improved recovery outcomes for affected individuals.

Switzerland

NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications.  NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.

NovaGo Therapeutics

Company Details